Lantheus Holdings Inc LNTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LNTH is a good fit for your portfolio.
News
-
Lantheus Sued by Novartis Entities for Patent Infringement
-
20 midcap stocks with 2024 upside ranging up to 62%, according to analysts
-
20 midcap stocks with 2024 upside ranging up to 62%, according to analysts
-
Lantheus and Point Biopharma shares drop on prostate cancer treatment data
-
Lantheus, POINT Biopharma Granted FDA Fast Track Designation for Lu-PNT2002 Prostate Cancer Drug
Trading Information
- Previous Close Price
- $65.21
- Day Range
- $63.76–65.27
- 52-Week Range
- $51.79–100.85
- Bid/Ask
- $63.88 / $65.24
- Market Cap
- $4.47 Bil
- Volume/Avg
- 603,019 / 843,029
Key Statistics
- Price/Earnings (Normalized)
- 11.15
- Price/Sales
- 3.53
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 834
- Website
- https://www.lantheus.com
Comparables
Valuation
|
Metric
|
LNTH
|
TIHE
|
688656
|
|---|---|---|---|
Price/Earnings (Normalized) | 11.15 | — | 432.38 |
Price/Book Value | 5.48 | — | 1.97 |
Price/Sales | 3.53 | — | 4.37 |
Price/Cash Flow | 9.61 | — | 18.52 |
Price/Earnings
LNTH
TIHE
688656
Financial Strength
|
Metric
|
LNTH
|
TIHE
|
688656
|
|---|---|---|---|
Quick Ratio | 5.33 | — | 1.81 |
Current Ratio | 5.80 | — | 2.68 |
Interest Coverage | 20.55 | — | 16.56 |
Quick Ratio
LNTH
TIHE
688656
Profitability
|
Metric
|
LNTH
|
TIHE
|
688656
|
|---|---|---|---|
Return on Assets (Normalized) | 30.46% | — | 0.40% |
Return on Equity (Normalized) | 73.91% | — | 0.47% |
Return on Invested Capital (Normalized) | 36.79% | — | 0.56% |
Return on Assets
LNTH
TIHE
688656
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Cxrzwcjvp | Mfxtthf | $69.8 Bil | |
ZTS
| Zoetis Inc Class A | Fnsvykzc | Qkfb | $68.9 Bil | |
HLN
| Haleon PLC ADR | Sxrwzxg | Zjlz | $37.7 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Kgqsgjlf | Zpjsv | $14.8 Bil | |
VTRS
| Viatris Inc | Yqgcszzxy | Wpx | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Qmzwqwx | Cdfbx | $11.9 Bil | |
CTLT
| Catalent Inc | Qbkcyxn | Pbxgpcg | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Qhyzlrgf | Rnqh | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Mwjntqmz | Vfsp | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Jsdmnrl | Bmhlxdx | $3.5 Bil |